AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureInformation ScienceNamed GroupsHealth Care
Hematopoietic Stem Cell TransplantationStem Cell TransplantationTransplantation, HomologousStem CellsTransplantation ConditioningGraft vs Host DiseaseTissue DonorsTransplantation ChimeraTransplantation, AutologousBone Marrow TransplantationHematologic NeoplasmsPeripheral Blood Stem Cell TransplantationHematopoietic Stem CellsGraft SurvivalLiver TransplantationHistocompatibility TestingHistocompatibilityWhole-Body IrradiationTreatment OutcomeFetal BloodKidney TransplantationEmbryonic Stem CellsCord Blood Stem Cell TransplantationSiblingsMesenchymal Stem Cell TransplantationAdult Stem CellsCell TransplantationHeart TransplantationPluripotent Stem CellsMyeloablative AgonistsCell DifferentiationLiving DonorsHLA AntigensLung TransplantationGraft vs Leukemia EffectImmunosuppressive AgentsRecurrenceAntigens, CD34LeukemiaGraft RejectionStem Cell NicheNeural Stem CellsSevere Combined ImmunodeficiencyRetrospective StudiesInduced Pluripotent Stem CellsMesenchymal Stromal CellsHematopoietic Stem Cell MobilizationTransplantation ImmunologyOrgan TransplantationBusulfanRemission InductionLymphocyte DepletionTime FactorsMultipotent Stem CellsUnrelated DonorsVidarabineCombined Modality TherapyMultiple MyelomaSpinal CordLymphocyte TransfusionTransplantationDisease-Free SurvivalSurvival RateStem Cell FactorHaploidyIslets of Langerhans TransplantationMelphalanCell LineageLeukemia, Myeloid, AcuteTransplantation, IsogeneicCells, CulturedT-LymphocytesPancreas TransplantationCyclophosphamideAntilymphocyte SerumFetal Stem CellsBone Marrow CellsSurvival AnalysisHaplotypesFollow-Up StudiesFetal TherapiesGranulocyte Colony-Stimulating FactorHematopoiesisBlood DonorsImmunosuppressionChimerismFlow CytometryCell ProliferationSpinal Cord InjuriesPrecursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Combined Chemotherapy ProtocolsCell SeparationHepatic Veno-Occlusive DiseaseHematologic DiseasesTransplantation, HeterologousSalvage TherapyCell Culture TechniquesAcute DiseaseGraft vs Tumor EffectStem Cell Research
TransplantsGraft-versus-Umbilical cordHSCTHuman leukocyte antigen-matMatched unrelated donorsGVHDFind a donorDonor's stem cellsMarrow TransplantationPeripheral blood stem cellUndergoing an allogeneicHematopoietic stem cellHematologyAllogeneic stem cellCurativeClinicalSickleMalignanciesAcute myelogenLacking matched siblinTransfusionCyclophosphamideChemotherapyHalf-matched2021ProphylaxisVeno-OcclusiComplicationsBone marrow donorTreat blood cancersOncologyEngraftmentHaplo-identicalPatient's bone marrowUnderwentConsidering a blood stem cell transDiseasesCancersType of transplantSevere aplastic anemiaUnrelated donor transplant
Transplants17
Graft-versus-9
  • We aimed to identify the risk factors that predict transplantation outcomes in patients with MF who underwent matched or mismatched allo-SCT using a uniform myeloablative conditioning regimen consisting of busulfan and fludarabine with tacrolimus and methotrexate-based graft-versus-host disease prophylaxis. (bvsalud.org)
  • The blood products should, if possible, undergo leukocyte reduction to prevent alloimmunization and CMV transmission and should be irradiated to prevent transfusion-associated graft versus host disease (GVHD) in HCT candidates. (medscape.com)
  • However, since there are transplant-related risks such as graft versus host disease and life-threatening infection, as well as organ toxicity, one could likely not be transplanted if their sickle cell disease was not under really good control or if they had minimal disease manifestations. (reachmd.com)
  • My principle research interests are in the prevention and therapy of graft-versus-host disease (GVHD) and in the use of graft-versus-leukemia to eradicate blood disorders. (harvard.edu)
  • Abstract Introduction: Graft-versus-host disease (GVHD) is a serious complication in allogeneic transplantation. (scielo.org)
  • The 3-year probability of total chronic graft-versus-host disease (GVHD) was 21.4% and 34.1% in the haploidentical and HLA-matched HSCT groups, respectively ( P =0.526). (blood-genomics.com)
  • The donor's cells are not as well matched to the patient's cells as in a standard allogeneic transplant, which increases the risk of complications such as graft-versus-host disease (GVHD) and graft rejection. (vanyahealth.com)
  • Low-dose post-transplant cyclophosphamide (PTCy) in conjunction with anti-thymocyte globulin (ATG) appears as a potentially effective graft-versus-host disease (GVHD) prevention strategy in haploidentical hematopoietic cell transplant (haplo-HCT). (biomedcentral.com)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
Umbilical cord21
HSCT14
  • Allogeneic hematopoietic stem cell transplantation, or HSCT, can cure sickle cell disease. (reachmd.com)
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the optimal treatment for pediatric patients with high-risk or intermediate-acute myeloid leukemia. (blood-genomics.com)
  • This study analyzed the clinical outcomes of 119 pediatric acute leukemia patients who underwent haploidentical HSCT ( n =68) or human leukocyte antigen (HLA)-matched HSCT ( n =51). (blood-genomics.com)
  • Analysis of the 3-year cumulative recurrence rate suggested no significant difference between the haploidentical HSCT group and HLA-matched HSCT group (cumulative incidence, 32.7% vs. 31.2%, P =0.801). (blood-genomics.com)
  • There was no difference in transplantation-related toxicity (TRT) in terms of infection, hepatic dysfunction, oral mucositis, and engraftment syndrome between the haploidentical HSCT and HLA-matched HSCT groups. (blood-genomics.com)
  • The study suggests that haploidentical HSCT shows comparable OS, LFS, and GRFS to HLA-matched HSCT in pediatric patients with acceptable complications, and can therefore be recommended as an effective alternative for this population. (blood-genomics.com)
  • Patients with an absence of cytotoxic T lymphocyte (CTL) function have a high risk for developing HLH, and could therefore benefit the most from early hematopoietic stem cell transplantation (HSCT). (biomedcentral.com)
  • Total body irradiation (TBI)-based-conditioning before allogeneic hematopoietic stem cell transplantation (allo-HSCT) is standard of care in patients with acute myeloid leukemia (AML) but can cause long-term morbidity. (biomedcentral.com)
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment modality for selected patients with acute myeloid leukemia (AML). (biomedcentral.com)
  • Since then, allogeneic hematopoietic stem cell transplantation (HSCT) has evolved to become a frequently used and effective therapy for many hematologic malignancies. (longdom.org)
  • The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
  • This is a quantitative, retrospective, observational, descriptive and analytical quantitative approach approaching the medical records of children and adolescents submitted to HSCT in a referral hospital service for this type of transplantation in the state of Rio Grande do Sul North (RN). (bvsalud.org)
  • The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
  • Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
Human leukocyte antigen-mat1
  • This study compared the effects of pre-transplantation minimal residual disease (pre-MRD) on outcomes in AML patients who underwent human leukocyte antigen-matched sibling donor transplantation (MSDT) or who received unmanipulated haploidentical allografts. (biomedcentral.com)
Matched unrelated donors3
GVHD10
  • This single-center study included patients with MF who underwent allo-SCT with a matched unrelated donor (MUD), matched related donor (MRD), or mismatched unrelated donor (MMUD) and received busulfan and fludarabine conditioning with methotrexate/tacrolimus-based GVHD prophylaxis. (bvsalud.org)
  • In a homogenous cohort of MF patients uniformly treated with busulfan/fludarabine myeloablative conditioning and methotrexate-based GVHD prophylaxis, we show that donor choice and HCT-CI are the 2 strongest predictors for improved survival after allo-SCT. (bvsalud.org)
  • GVHD is a common problem after a transplant using donor cells. (bmtinfonet.org)
  • We have a series of clinical trials available to evaluate several different strategies to prevent GVHD, such as T cell depletion and the use of novel immunosuppressive agents. (harvard.edu)
  • Causes of mortality in those patients were severe viral pneumonia, post-transplantation hemophagocytic syndrome and meningeal GVHD refractory to ruxolitinib. (scielo.org)
  • These results suggested that ATG/PTCy (low-dose) can reduce both acute and chronic GVHD as compared with standard ATG-based prophylaxis using maternal donor or collateral relatives at particular high GVHD risk. (biomedcentral.com)
  • In this prospective trial, results indicated that low-dose PTCy is sufficient to lower acute GVHD in mouse model, partly due to the boosting of fast regulatory T cell (Treg) reconstitution. (biomedcentral.com)
  • 12 months after first HCT with acceptable rates of GVHD and donor engraftment. (biomedcentral.com)
  • T-cell depletion is an approach that enhances procedure tolerability by reducing acute and chronic GVHD related morbidity and mortality. (biomedcentral.com)
  • We have employed in vivo T-cell depletion with alemtuzumab for over a decade at the University of Chicago and confirmed lower rates of acute and chronic GVHD with similar overall survival to T cell repleted HCT [ 10 ]. (biomedcentral.com)
Find a donor4
  • We try to find a donor who has 10 antigens that match 10 of the patient's antigens. (mdanderson.org)
  • Is an option for many patients who need a stem cell transplant but cannot find a donor in their family or in donor registries. (fondationhmr.ca)
  • In order to perform this treatment, doctors must first find a donor who has a rare mutation that makes them resistant to the virus. (healthmedicinet.com)
  • A misconception about BMT is that it is almost impossible to find a donor, particularly if you are from a certain race or ethnicity. (fredhutch.org)
Donor's stem cells4
Marrow Transplantation13
Peripheral blood stem cell3
  • An overview of bone marrow, peripheral blood stem cell and cord blood transplantation. (bmtinfonet.org)
  • This has led to the utilization of marrow, cord, peripheral blood stem cell and haploidentical stem cell sources, and novel reduced toxicity or reduced intensity conditioning regimens to transplant non-malignant disorders such as immune dysfunctions, marrow failure syndromes, metabolic disorders and hemoglobinopathies. (wustl.edu)
  • Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease. (unicatt.it)
Undergoing an allogeneic1
  • After undergoing an allogeneic haematopoietic stem cell transplantation (alloHCT), patients need intensive physiological and psychological rehabilitation. (mdpi.com)
Hematopoietic stem cell2
  • A hematopoietic stem cell transplant replaces faulty cells so the body can produce normal, healthy cells again. (mdanderson.org)
  • Second allogeneic hematopoietic stem cell transplant (HCT) remains as an option for disease relapse after initial HCT. (biomedcentral.com)
Hematology1
  • The Baptist Cancer Center Malignant Hematology and Transplant Program is a FACT-accredited program that performs adult autologous and allogeneic transplantation. (bethematch.org)
Allogeneic stem cell20
Curative3
  • Hematopoietic stem cell transplantation is the only potentially curative therapy, but it is only an option for select patients. (cancernetwork.com)
  • At Gamida Cell, we are at the forefront of developing and commercializing potentially curative medicines for patients by harnessing our proprietary NAM cell expansion technology. (seekingalpha.com)
  • Summary The curative potential of BMT in SCD is irrefutable, with outstanding results in children following a myeloablative conditioning regimen and a matched sibling donor transplant. (johnshopkins.edu)
Clinical12
  • B-cell maturation antigen (BCMA) is the current target antigen of choice for most CAR T-cell products under investigation for MM. However, their shortcomings deal with logistical and clinical challenges, including limited availability, manufacturing times, and toxicities. (bvsalud.org)
  • The superior clinical outcomes of allogeneic SCT versus chemotherapy alone as post-remission treatment could be related to the graft-versus-leukemia (GVL) effects of recovered donor T cells. (biomedcentral.com)
  • So what are the realities and clinical outcomes associated with hematopoietic stem cell transplantation in sickle cell disease? (reachmd.com)
  • Severe combined immunodeficiency (SCID), also known as Swiss-type agammaglobulinemia, is a rare genetic disorder characterized by the disturbed development of functional T cells and B cells caused by numerous genetic mutations that result in differing clinical presentations. (wikipedia.org)
  • These babies, if untreated, usually die within one year due to severe, recurrent infections unless they have undergone successful hematopoietic stem cell transplantation or gene therapy in clinical trials. (wikipedia.org)
  • For this patient, the transplant team at Hôpital Maisonneuve-Rosemont, which included Dr. Jean Roy, hematologist and clinical researcher at Maisonneuve-Rosemont Hospital and full professor at the Université de Montréal's Faculty of Medicine, aimed to perform an allograft (a transplant in which the donor is someone other than the patient himself). (fondationhmr.ca)
  • It was after we had exhausted all our treatment options that UM171, which had already been proven in a clinical trial in blood cancer patients, came into play. (fondationhmr.ca)
  • This study aims to monitor the long-term health of patients who have received a donor stem cell transplant from the NIH Clinical Center. (nih.gov)
  • The clinical presentation of patients with aplastic anemia includes signs and symptoms related to the decrease in bone marrow production of hematopoietic cells. (medscape.com)
  • T-cell responses correlate directly with clinical symptoms, and were better predictors of HHV-6 disease than viral load or total CD3+ counts. (hhv-6foundation.org)
  • Scientists working in basic, translational, and clinical cancer metabolism research are invited to join the Academy in New York on April 17th to discuss the intersection between cell signaling and metabolism. (nyas.org)
  • The objective of this report is to review the most recent clinical trials involving blood and BMT for SCD and to discuss novel approaches to overcome the many barriers to successful use of BMT for SCD. (johnshopkins.edu)
Sickle9
  • Let's learn more about how and when hematopoietic stem cell transplantation is used in the management of sickle cell disease. (reachmd.com)
  • Well, it's transplanting blood stem cells from a donor without sickle cell disease into a recipient who does have sickle cell disease. (reachmd.com)
  • The blood cells are harvested from the donor and stored, and then the sickle cell disease patient is given high doses of chemotherapy to get rid of all the remaining blood cells in the bone marrow in order for them to be able to receive the healthy donated cells. (reachmd.com)
  • The cells from the donor which are healthy are then infused into the sickle cell patient through a simple IV. (reachmd.com)
  • This essentially cures the patient of sickle cell disease. (reachmd.com)
  • But unfortunately, only about 20% of patients with sickle cell disease in the United States have a matched donor. (reachmd.com)
  • So the goal is to transplant someone with sickle cell disease before they become too sick, particularly before they develop significant organ damage, such as kidney disease, liver disease, or heart disease, that might even preclude their ability to safely undergo the rigors of a transplant. (reachmd.com)
  • The main requirement for a donor is to not have sickle cell disease or infection, such as HIV or hepatitis C. But what's important to know is that it's perfectly fine for the donor to have sickle cell trait. (reachmd.com)
  • This procedure is typically used to treat blood cancers such as leukemia, lymphoma, and multiple myeloma, as well as other disorders such as sickle cell anemia and thalassemia. (vanyahealth.com)
Malignancies3
  • By inducing T-cell kill of target cancer cells, chimeric antigen receptor (CAR) T-cell therapies have improved outcomes of patients with hematologic malignancies. (bvsalud.org)
  • They observed that impairing Ythdf2 function did not alter the types of cells that were subsequently produced, nor did it lead to increased blood cell malignancies. (scitechdaily.com)
  • This global trial evaluated omidubicel versus standard cord blood in patients with hematologic malignancies, who needed a bone marrow transplant, but did not have a suitable match donor. (seekingalpha.com)
Acute myelogen1
  • Aim: To report our experience with ALOHT in acute myelogenous leukemia (AML), analyzing patient age at transplantation in different periods and transplant results in different age groups. (scielo.org)
Lacking matched siblin1
  • For patients lacking matched sibling donors, haploidentical donors are an option. (blood-genomics.com)
Transfusion2
  • Treatment of thrombopathy requires, first of all symptomatic measures: haemostatic glues, desmopressin and the blood transfusion which must be only reserved for the difficult gestures or for the high hemorrhagic risk. (longdom.org)
  • The process is similar to getting a blood transfusion. (medlineplus.gov)
Cyclophosphamide1
Chemotherapy15
  • For example, people who have stem cell transplantation go through intensive chemotherapy before treatment. (clevelandclinic.org)
  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with a poor prognosis and considered incurable with standard conventional chemotherapy. (bvsalud.org)
  • To transplant new healthy cells, the old ones must first be killed with chemotherapy or radiation before the new ones can be implanted. (expertchikitsa.com)
  • Chemotherapy will be given to you before the transplant to remove any stem cells in your bone marrow that aren't functioning properly and to prepare your bone marrow to receive new stem cells. (expertchikitsa.com)
  • We extract blood cells, treat the cancer with high-dose chemotherapy , then place the cells back into the patient. (mdanderson.org)
  • Once the cancer is less active and the patient has been pre-treated with chemotherapy (known as conditioning), he or she receives the donor's healthy stem cells. (mdanderson.org)
  • In this type of transplant, the patient's own stem cells are collected before the high-dose chemotherapy and/or radiation therapy is given. (vanyahealth.com)
  • After the chemotherapy and radiation therapy, the stored stem cells are thawed and returned to the patient's body. (vanyahealth.com)
  • This type of transplant is used when the patient's own cells are not damaged or diseased, but are being used as a rescue therapy after high-dose chemotherapy or radiation therapy. (vanyahealth.com)
  • The treatment options for disease relapse after HCT include withdrawal of immune suppression, chemotherapy, second allogeneic transplant, cytokine and adoptive cell therapy and donor lymphocyte infusion [ 1 ]. (biomedcentral.com)
  • Sometimes the amount of radiation, chemotherapy or both that is needed to treat a cancer is so high that a patient's stem cells will be badly damaged or destroyed by these treatments. (fredhutch.org)
  • Ablative (myeloablative) treatment -- High-dose chemotherapy, radiation, or both are given to kill any cancer cells. (medlineplus.gov)
  • Stem cells are removed from you before you receive high-dose chemotherapy or radiation treatment. (medlineplus.gov)
  • After high-dose chemotherapy or radiation treatments, your stems cells are put back in your body to make normal blood cells. (medlineplus.gov)
  • A stem cell transplant is usually done after chemotherapy and radiation is complete. (medlineplus.gov)
Half-matched3
  • In some instances, a half-matched (haplo-identical) relative donor is used. (bethematch.org)
  • The half-matched type of transplant is called haploidentical. (wikipedia.org)
  • Haploidentical transplant, also known as half-matched transplant, is a type of allogeneic transplant where the donor and the recipient are not a perfect match but share one haplotype (half of the genetic material) in common. (vanyahealth.com)
20212
Prophylaxis1
Veno-Occlusi1
  • Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. (harvard.edu)
Complications5
  • In addition to increasing the number of stem cells, UM171 greatly reduces the risk of long-term immunological complications. (fondationhmr.ca)
  • This study is investigating a new method for collecting blood stem cells from donors to see if it reduces transplant complications, such as rejection, in patients who have blood diseases. (nih.gov)
  • If one of the brothers and sisters is compatible, we speak about geno-identical allogeneic transplantation having the advantage of reducing the complications post-transplantation. (longdom.org)
  • Could some complications of CAR-T cell therapy be secondary to HHV-6 infection? (hhv-6foundation.org)
  • Our depth and breadth of knowledge allows us to treat both common and very rare blood diseases, and help manage any complications that might arise, helping you get better faster. (fredhutch.org)
Bone marrow donor2
  • Only 30 percent of patients have a bone marrow donor match available in their families, according to the US Department of Health and Human Services. (scitechdaily.com)
  • David Vetter, the original "bubble boy", had one of the first transplantations also, but eventually died because of an unscreened virus, Epstein-Barr (tests were not available at the time), in his newly transplanted bone marrow from his sister, an unmatched bone marrow donor. (wikipedia.org)
Treat blood cancers2
Oncology2
  • [ 5 ] The Pediatric Haemato-Oncology Italian Association recommends HCT from a matched sibling donor for severe aplastic anemia, and if a matched donor is not available, options include immunosuppressive therapy or unrelated donor HCT. (medscape.com)
  • This is a world first stemming from the discovery of a team of researchers from the Institute of Hemato-oncology and Cellular Therapy (iHOTC) of Hôpital Maisonneuve-Rosemont and the Institute for Research in Immunology and Cancer of the University of Montreal, whose research benefited greatly from the support of the HMR Foundation and its donors. (fondationhmr.ca)
Engraftment2
  • The role of the adult donor cells is to hasten the early engraftment process and render the transplant easier and safer,' Dr Koen van Besien, one of the lead doctors evaluating the New York patient, told NBC. (healthmedicinet.com)
  • The primary endpoint of the study was time to neutrophil engraftment, or the time it took for the white blood cells to recover following transplantation. (seekingalpha.com)
Haplo-identical1
  • In the absence of a family or unrelated donor, stem cells from a semi-identical (i.e., partially matched) family donor, also known as a "haplo-identical donor", may be considered under certain conditions. (fondationhmr.ca)
Patient's bone marrow2
  • The cells are remarkable in that they can find their way into the recipient's bone marrow, where they begin to divide and repopulate the patient's bone marrow as his or her own. (reachmd.com)
  • This occurs when the donated cells do not engraft or grow properly in the patient's bone marrow. (vanyahealth.com)
Underwent1
  • We conducted an analysis of 164 patients with BPDCN from 78 centers who underwent allo-HCT between 2007-2018 using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). (bvsalud.org)
Considering a blood stem cell trans1
  • Are you considering a blood stem cell transplant? (nih.gov)
Diseases8
  • This development could make these cells available to more people, and be more readily accepted in those who undergo adult stem cell treatments for conditions such as leukemia, blood disorders, immune system diseases, and other types of cancers, but who do not have an appropriate available bone marrow match. (scitechdaily.com)
  • In addition, we are committed to graft engineering and vaccine development to enhance the ability of transplantation to control blood diseases. (harvard.edu)
  • PURPOSE OF REVIEW: The role of hematopoietic cell transplantation in non-malignant disorders has increased exponentially with the recognition that multiple diseases can be controlled or cured if engrafted with donor-derived cells. (wustl.edu)
  • Giving patients stem cells from someone else may help to cure many patients with certain immune diseases. (zhihuiya.com)
  • The NHLBI leads or sponsors studies for patients who have heart, lung, blood, or sleep related diseases or disorders. (nih.gov)
  • Blood Disorders, Bone Marrow Failure Syndrome, Immunodeficiencies and other diseases like Neuroblastoma and Solid Tumours. (cryosave.co.za)
  • A comprehensive list of current treatable diseases and therapies can be found on Parents' Guide to Cord Blood . (cryosave.co.za)
  • Alternative allogeneic donor sources for transplantation for childhood diseases: unrelated cord blood and haploidentical family donora. (cryosave.co.za)
Cancers4
  • Blood cancers multiply uncontrollably, hindering the growth of these cells. (mdanderson.org)
  • The cord blood helps fight blood based cancers - like the leukemia the woman was suffering from, while the bone marrow provides stem cells to the body. (healthmedicinet.com)
  • Blood and marrow transplant (BMT) is often the best therapy for blood cancers. (fredhutch.org)
  • For many cancers, the donor's white blood cells may attack any remaining cancer cells, which are seen as foreign, similar to when white cells attack bacteria or viruses when fighting an infection. (medlineplus.gov)
Type of transplant2
  • In this type of transplant, stem cells are taken from a donor (usually a close relative or sibling) and given to the patient. (vanyahealth.com)
  • This type of transplant is used when the patient's own cells are damaged or diseased. (vanyahealth.com)
Severe aplastic anemia1
  • In addition, the rate of graft rejection, i.e. the destruction of the injected cord cells at the time of transplantation by the recipient's immune system, is very high in patients with severe aplastic anemia who have received multiple blood transfusions. (fondationhmr.ca)
Unrelated donor transplant1
  • So are there any downsides of undergoing an unrelated donor transplant? (reachmd.com)